ID: ALA1269706

Max Phase: Preclinical

Molecular Formula: C15H14N2O2S

Molecular Weight: 286.36

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc2oc(Nc3ccc(SC)cc3)nc2c1

Standard InChI:  InChI=1S/C15H14N2O2S/c1-18-11-5-8-14-13(9-11)17-15(19-14)16-10-3-6-12(20-2)7-4-10/h3-9H,1-2H3,(H,16,17)

Standard InChI Key:  AGAAUWCDNZOZSR-UHFFFAOYSA-N

Associated Targets(non-human)

Arachidonate 5-lipoxygenase 121 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 286.36Molecular Weight (Monoisotopic): 286.0776AlogP: 4.30#Rotatable Bonds: 4
Polar Surface Area: 47.29Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.40CX Basic pKa: 0.24CX LogP: 3.91CX LogD: 3.91
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.72Np Likeness Score: -1.49

References

1. Song H, Oh SR, Lee HK, Han G, Kim JH, Chang HW, Doh KE, Rhee HK, Choo HY..  (2010)  Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors.,  18  (21): [PMID:20870413] [10.1016/j.bmc.2010.08.047]

Source